Axsome Therapeutics, Inc. (AXSM) financial statements and ratios from SEC XBRL: revenue $0.8B (TTM), net margin -28.7%, revenue growth 65.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $638.50M |
| Revenue (TTM) | $0.8B |
| Net Margin | -28.7% |
| Operating Margin (TTM) | -22.7% |
| Net Debt / EBITDA | 0.7 |
| Revenue Growth (YoY) | 65.5% |
| EPS Growth (YoY) | -38.6% |
| FCF Growth (YoY) | -27.0% |
| Price / Book | 130.58 |
| Price / Sales | 14.09 |
| FCF Yield | -1.6% |
| Altman Z-Score | 8.44 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
AXSM overview · AXSM earnings · AXSM KPIs · AXSM documents · AXSM ownership · AXSM peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.